博腾股份表示，2025年前三季度，随着公司客户管线、产品管线的不断丰富和拓展，研发技术能力和产 品交付能力的不断提升，公司面向国内及国际市场的总体业务均实现了平稳增长，公司预计实现营业收 入24.8亿元至25.8亿元，同比增长17%至21%。受益于公司营业收入增长，规模化效应显现，公司盈利 能力恢复性提升。此外，公司持续落地降本增效和精益运营举措，运营效率提升，公司整体毛利率同比 持续改善。 北京商报讯（记者 丁宁）10月13日晚间，博腾股份（300363）发布2025年前三季度业绩预告显示，公 司预计前三季度实现归属净利润7320万元至8820万元，同比扭亏为盈。 ...

Company Announcements - Northern Rare Earth received a warning letter from the Inner Mongolia Securities Regulatory Bureau due to undisclosed non-operating fund occupation by related parties, amounting to 8.9485 million yuan, which has been fully repaid [2] - Aosheng Electronics reported that revenue from controllable nuclear fusion-related products will account for less than 1% of its main business revenue in the first half of 2025 [2] - Yiyi Co. is planning to acquire a pet food company, leading to a stock suspension [3] - Sanmei Co. expects a net profit increase of 172%-193% year-on-year for the first three quarters, driven by a significant rise in the average price of fluorinated refrigerants [4] - Feirongda anticipates a net profit increase of 111%-130% year-on-year for the first three quarters, with growth in AI server cooling-related business revenue [4] - Zhongshi Technology expects a net profit increase of 74%-104% year-on-year for the first three quarters, benefiting from increased shipments of thermal materials and components [4] - Juxin Technology forecasts a net profit increase of 113% year-on-year for the first three quarters, with sales revenue from edge AI processor chips increasing significantly [4] - Chuangjiang New Materials expects a staggering net profit increase of 2058%-2243% year-on-year for the first three quarters [4] - New China Life Insurance anticipates a net profit increase of 45%-65% year-on-year for the first three quarters [4] Investment & Contracts - Fostda plans to invest 1 billion yuan in the construction of an intelligent manufacturing project for marine engineering and equipment [11] Shareholding Changes - Dongxin Co. has set an initial transfer price of 82.5 yuan per share for its inquiry transfer, which is a 16% discount from the closing price [11] - China Jushi has obtained a commitment letter for a stock repurchase loan of up to 630 million yuan [12] - Tianji Co. has reduced its holdings by 2.9996% of the company's shares and has terminated its reduction plan early [3] Performance & Operations - Yingweike reported a net profit of 183 million yuan for the third quarter, an increase of 8.35% year-on-year [13] - Chenguang Biological expects a net profit increase of 344%-402% year-on-year for the first three quarters [14] - Meili Ecology's subsidiary won a bid for a 2.375 billion yuan urban renewal project in Shenzhen [18] Stock Price Movements - Hezhu Intelligent has not generated any revenue related to nuclear fusion concepts [19] - Jinli Yongci confirmed that its recent stock price fluctuations are not due to undisclosed significant matters [20] Other Developments - Heng Rui Medicine's subsidiary received approval for clinical trials of SHR-1905 injection [24] - Renfu Medicine received a drug registration certificate for Dapoxetine Hydrochloride Tablets, which are expected to generate approximately 1.1 billion yuan in sales in 2024 [26]

格隆汇10月13日丨博腾股份(300363.SZ)发布2025年前三季度业绩预告，预计归属于上市公司股东的净 利润为7,320万元至8,820万元，同比扭亏为盈。报告期内，公司客户管线和产品管线持续拓展，研发技 术与交付能力提升，国内外业务平稳增长，营业收入同比增长17%-21%，规模化效应显现，叠加降本增 效和精益运营推进，毛利率持续改善，盈利能力恢复性提升。 ...

Group 1 - The company expects a net profit attributable to shareholders of 73.2 million to 88.2 million yuan for the first three quarters, marking a turnaround from losses in the previous year [1] - The net profit excluding non-recurring gains and losses is projected to be between 50 million and 65 million yuan, also indicating a recovery from losses year-on-year [1] - The company anticipates total operating revenue of 2.48 to 2.58 billion yuan, representing a year-on-year growth of 17% to 21% [1] Group 2 - The growth in revenue is attributed to the continuous expansion of the company's client and product pipelines, as well as improvements in research and development capabilities and product delivery [1] - The company has implemented cost reduction and efficiency enhancement measures, leading to improved operational efficiency and a continuous increase in overall gross margin year-on-year [1]

每经AI快讯，10月13日，博腾股份(300363.SZ)公告称，博腾股份发布2025年前三季度业绩预告，预计 归属于上市公司股东的净利润为7,320万元至8,820万元，同比扭亏为盈。报告期内，公司客户管线和产 品管线持续拓展，研发技术与交付能力提升，国内外业务平稳增长，营业收入同比增长17%-21%，规模 化效应显现，叠加降本增效和精益运营推进，毛利率持续改善，盈利能力恢复性提升。 ...

Profit Forecast - The company expects a net profit attributable to shareholders of between 73.20 million and 88.20 million yuan, a turnaround from a loss of 206.43 million yuan in the same period last year [4]. - The net profit attributable to shareholders after deducting non-recurring gains and losses is projected to be between 50.00 million and 65.00 million yuan, compared to a loss of 213.50 million yuan in the previous year [4]. - Non-recurring gains and losses are expected to impact net profit by approximately 23.20 million yuan, compared to 7.07 million yuan in the same period last year [4]. Revenue Growth - The company anticipates total operating revenue of 2.48 billion to 2.58 billion yuan, representing a year-on-year growth of 17% to 21% [6]. - The company has seen a recovery in profitability due to revenue growth and the realization of scale effects [7]. Operational Efficiency - Continuous implementation of cost reduction and efficiency enhancement measures has improved overall operational efficiency and gross margin [7].

Core Viewpoint - The Biotech Index (970038) closed at 2325.47 points, down 1.85%, with a trading volume of 31.496 billion yuan and a turnover rate of 2.07% [1] Group 1: Index Performance - On the day, 6 out of the index's constituent stocks rose, with Huace Testing leading with a 2.51% increase, while 44 stocks declined, with Boteng Co. leading the decline at 6.27% [1] - The top ten constituent stocks of the Biotech Index are primarily in the pharmaceutical and biotechnology sectors, with notable declines in major stocks like Mindray Medical and Changchun High-tech [1] Group 2: Stock Details - The top ten constituent stocks by weight include: - Mindray Medical (13.81% weight) at 235.20 yuan, down 2.81%, with a market cap of 285.166 billion yuan [1] - Changchun High-tech (5.41% weight) at 132.06 yuan, down 3.11%, with a market cap of 53.872 billion yuan [1] - Kanglong Chemical (4.66% weight) at 31.76 yuan, down 3.99%, with a market cap of 56.475 billion yuan [1] - Other notable stocks include Taige Pharmaceutical and Aimeike, both showing declines [1] Group 3: Capital Flow - The Biotech Index constituent stocks experienced a net outflow of 722 million yuan from main funds, while retail investors saw a net inflow of 534 million yuan [3] - Specific stocks like Mindray Medical and Changchun High-tech had varying levels of net inflow and outflow from different investor categories, indicating mixed investor sentiment [3]

Core Insights - The company, Boten Co., reported that as of September 19, 2025, the total number of shareholders (including both regular accounts and margin trading accounts) is 51,542 [1] Summary by Categories - **Shareholder Information** - The total number of shareholders is 51,542 as of the specified date [1]

Group 1 - The CRO sector led the market with a rise of 3.5% on September 30 [1] - Haoyuan Pharmaceutical increased by 6.58% [1] - WuXi AppTec rose by 6.21% [1] - Boteng Co., Ltd. saw an increase of 4.99% [1] - MediSci and Northgrip, as well as Chengda Pharmaceutical, all experienced gains exceeding 4% [1]

Summary of Conference Call Records Industry Overview - The conference call primarily discusses the **biotechnology and pharmaceutical contract development and manufacturing organization (CDMO)** industry, focusing on companies like **WuXi AppTec**, **Kailai Ying**, and **Boteng** [1][2]. Key Points and Arguments 1. **Order Growth and Capacity Utilization** - WuXi AppTec and Kailai Ying accelerated overseas MNC orders in Q3, leading to increased capacity utilization. Small molecule oral drug orders began to materialize in Q3, expected to contribute to revenue in Q4 and increase gradually next year [1][2]. 2. **Emerging Business Performance** - Kailai Ying's emerging business is nearly at full capacity, particularly in its Tianjin factory, with recent price increases. Boteng's traditional small molecule business also raised prices by approximately 8-10% due to improved capacity utilization, primarily targeting biotech clients [1][5]. 3. **Biosimilar Exemption Benefits** - The exemption for Phase III biosimilars is a significant positive for the large molecule CDMO sector, expected to accelerate overseas orders in Q4 or the first half of next year, positively impacting media and large molecule CGM [1][6]. 4. **Domestic CRO Demand Surge** - Domestic CRO companies saw a further increase in demand in Q3, particularly in pharmacodynamics and toxicology. In vitro pharmacodynamics orders showed a year-on-year growth of 20-30% in H1, reaching 35-40% in Q3, with expectations for continued growth into H1 2026 [1][7][8]. 5. **Biotech Industry Budget Management** - The biotech industry's budget management in 2025 is more relaxed compared to 2024, with reduced pressure on order discounts and price negotiations, leading to an anticipated increase in biotech order prices [1][9]. 6. **Price Trends for Experimental Monkeys** - The price of experimental monkeys increased significantly in Q3, averaging around 95,000 yuan in H1, rising to 110,000-120,000 yuan by late August, reflecting increased demand [1][10]. 7. **Clinical Sector Performance** - The clinical sector saw a 5% growth in total volume in Q3 compared to Q2. Although prices have not yet increased, there is potential for industry-wide price hikes in Q4 due to rising demand and relaxed budgets [1][11]. 8. **Competitive Strategies in Clinical Sector** - Major companies in the clinical sector are adjusting their competitive strategies. For instance, companies like Kailai Ying and KunTuo are focusing on high-margin orders and reducing participation in price wars, which may support future price increases [1][12]. 9. **Impact of External Factors** - The influence of external factors, such as Trump's tweets, on CDMO businesses like WuXi AppTec is limited, as these companies have already engaged with U.S. counterparts regarding capacity issues [1][13][14]. Additional Important Insights - The overall sentiment in the industry is optimistic, with expectations for continued growth in orders and potential price increases across various segments, driven by improved demand and strategic adjustments by key players [1][2][9].